Aurora Cannabis Takeover Fight: Curaleaf Lifts Hostile Bid to $5

A hostile bid gets bigger, and so does the fight

Curaleaf began its pursuit of Aurora Cannabis politely and in private. Two months later, the two companies are fighting in public with regulatory filings, accusations of bad faith, and a possible rival bidder. For Aurora shareholders, and for anyone thinking about buying the Nasdaq-listed stock, the question is whether the takeover premium has more room to grow or whether the market already has most of it priced in.

Curaleaf made its offer public in early August 2026 after it said Aurora had not responded to private approaches. Aurora disputed that account.12 The first bid valued Aurora at about $4 a share, paid as 0.3463 Curaleaf subordinate voting shares plus 75 cents in cash. The offer also capped the consideration at $5 a share.14 In total, the first offer was worth about $272 million.2 On October 5, Curaleaf raised its bid by 25% to $5 a share, now 0.4013 Curaleaf shares plus $1 in cash, priced off Curaleaf's October 2 close.23 It also raised the cap to $6 a share and pushed the expiry date to December 4.16

Curaleaf says the new price is an 86% premium to Aurora's unaffected 30-day volume-weighted average price of $2.75 as of August 10.2 Aurora's board has not changed course. It still tells shareholders to take no action while a special committee of independent directors reviews the revised terms.6

How the bid got here

The two sides tell different stories about how the bid began. Aurora says it received letters from Curaleaf dated June 23 and July 7. It says the first named no price and the second did not say how the offer would be split between cash and stock.14 Aurora also says it talked with Curaleaf as recently as August 12, which contradicts Curaleaf's claim that it was ignored.14 Curaleaf CEO Boris Jordan says Aurora never made a counteroffer, which he argues shows management cares more about keeping its jobs than about creating value for shareholders.18

Aurora's board formally rejected the bid in early September, calling it inadequate. CEO Miguel Martin argued that shareholders would be swapping a debt-free company for exposure to an acquirer carrying more than $1 billion in debt.18 Aurora backed that up with Curaleaf's own financial statements. They show $500 million of senior secured notes at 11.5% interest as of June 30, 2026.8 Aurora also attacked the structure of the deal. Its shareholders would own 7.7% of the combined company but hold only 3.2% of the votes.12

The fight then moved to the Alberta Securities Commission. Curaleaf asked regulators to stop Aurora's at-the-market (ATM) share sales. It argued that issuing new stock below the offer price destroys shareholder value.3 Aurora replied that the ATM program was disclosed months before the bid, had been inactive for several weeks, and had gone unused for three years before February 2026.9 Aurora filed its own complaint. It said Curaleaf's bid circular left out pro forma financial statements, did not stay open for the legally required minimum period, and was not published in a French-language outlet.7 Aurora largely got what it asked for. Curaleaf agreed to provide pro forma financials and extend the expiry to December 4.5

The numbers behind the bid

The dollar amounts explain why this fight matters beyond the two companies. Curaleaf describes itself as the world's largest cannabis company, with a market value of about $2.6 billion.17 It says a combined company would operate in 17 countries, with more than $1.5 billion in trailing 12-month revenue and close to $350 million in adjusted earnings.6 What Curaleaf most wants is Aurora's more than 50 tons of annual EU-GMP cultivation and manufacturing capacity. That certification is required to sell medical cannabis into regulated European markets.6 Aurora is still expanding that footprint. It recently enlarged its EU-GMP-licensed facility in Germany.4

Aurora says Curaleaf wants to buy its cash, its EU-GMP assets, and its future growth at a discount.8 Aurora has cited a debt-free balance sheet and about CA$149 million in cash. Darren Gleeman of MBO Ventures made a similar point in a September column. He noted that Aurora held more cash and short-term investments than the roughly $51 million in cash Curaleaf planned to pay under the first offer.2 In effect, Aurora shareholders would partly be funding their own buyout. Gleeman also pointed out that the original $5 cap limited shareholders' gains while leaving them fully exposed if Curaleaf's stock fell.2

The revised offer addresses both complaints, but only partly. The cash portion rose 33%, and the cap rose 20%.16 Most of the consideration is still Curaleaf stock, so what Aurora holders would actually receive depends on how Curaleaf shares perform.16

A possible rival bidder

The biggest recent development is the report of a second suitor. Organigram, a Canadian licensed producer partly owned by British American Tobacco, has held talks with Aurora in recent weeks about a possible deal, according to the newsletter Cultivated. Both companies declined to comment.6 An Organigram deal would give BAT indirect exposure to one of the largest medical cannabis businesses across Canada, Europe, and Australia. A competing bid could force Curaleaf either to raise its price again or to walk away.6

Curaleaf reacted angrily. It said it was "outraged" that it had been denied due diligence access while a company worth about $200 million appeared to be welcome.17 It also asked whether Aurora investors would rather hold the shares of a company with limited Canadian reach or those of the global market leader.17 One industry newsletter noted that Aurora has no obligation to open its books to a hostile bidder, since doing so would make the bid no longer hostile. The same writer read the 25% increase as a sign that large shareholders thought the first offer was too low.11

Where the coverage disagrees

Most outlets agree on the basic terms. They differ on three points that matter to investors.

Whether the revised bid is formal yet. A blog summary citing StreetInsider says Curaleaf formally amended its offer on October 6.16 Aurora, however, told reporters the October 5 announcement was not a formal revised bid and that it had not received the documents needed for a review.15 By the time of a later Aurora statement, Martin was calling the filing of the revised bid "the next step in the process, not a deadline."17 The most likely explanation is that the documents arrived within days of each other. Either way, the board's formal recommendation is still pending.

How weak Aurora really is. One outlet described Aurora as part of a group of "struggling" Canadian producers and said Curaleaf had not responded to the rejection. That description does not match the rest of the coverage. Curaleaf answered the rejection the same day,18 and Aurora's case rests on its balance sheet, not on hardship.8

What shareholders are signaling. Jordan says every Aurora holder Curaleaf has met supports the strategic logic of a merger.2 Supporting the logic of a merger is not the same as accepting the price, though. And the bid increase looks more like a response to resistance than a sign that shareholders are ready to tender.11

Is Aurora stock a buy?

Aurora traded at $2.76 before the offer and around $4.30 on October 13.6 Another report put the gain since the first bid at about 25%. At $4.30, the stock sits roughly 14% below the headline $5 offer. That gap suggests investors see real doubt that the deal will close on these terms. It also reflects the fact that the $5 figure depends on Curaleaf's share price.

In our view, the stock is not a clear buy at this price. The upside cases are a higher Curaleaf bid or a bidding war involving Organigram. Both are possible but unconfirmed, and Cultivated says no deal is guaranteed.6 The downside case is that Curaleaf gives up. In that scenario, the stock could fall back toward the pre-bid level of about $2.75, a much larger move than the gap to the offer price. One Motley Fool analysis advised most investors to stay on the sidelines, and suggested existing holders could lock in their gains.12 Another argued the stock could climb further, pointing to the board's apparently more serious review of the bid.

The bitterness between the companies also matters after a deal closes. Even if Curaleaf wins, the fight could make it hard to combine two very different corporate cultures.12 Curaleaf also needs a majority of Aurora shareholders to tender, which will be difficult with the board opposed.12

In short, Aurora is now a bet on how the takeover contest plays out, not on the business itself. Buying at about $4.30 means betting that a third party or a higher Curaleaf bid will push the price above $5 before December 4. For existing holders, the case for selling some shares and keeping the rest for possible upside looks stronger than the case for buying more.